Jubilant receives ANDA approval for Levofloxacin

June 24, 2015 | Wednesday | News | By BioSpectrum Bureau

Jubilant receives ANDA approval for Levofloxacin

The approval is for Levofloxacin Tablets, 250mg and 500mg

Jubilant Life Sciences has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (US FDA) for Levofloxacin Tablets, 250mg and 500mg.

Levofloxacin Tablets are the generic version of Levaquin Tablets (of Ortho-McNeil), which is used for the treatment of adults with infections such as pneumonia, bacterial sinusitis, chronic bronchitis, skin and skin structure infections, chronic bacterial prostatitis, urinary tract infections and inhalational anthrax.

The total market size for Levofloxacin Tablets as per IMS is $28 million per annum.